Clinical trial · Interventional
Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer
Feasibility Study of Lung Cancer Screening Using Cell-Free DNA Liquid Biopsy at Home in High-Risk Current and Former Smokers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial investigates how practical and doable (feasibility) cell-free deoxyribonucleic acid (DNA) liquid biopsy is in screening high-risk patients for lung cancer. Currently, a low dose computed tomography (CT) scan is used to screen for lung cancer, however, due to various factors, few high-risk patients are screened. Liquid biopsy utilizes technology that can detect small amounts of DNA shed by cancer cells and may be able to spot lung cancer at an earlier stage. If a positive result comes back from the liquid biopsy, a patient may be more willing to get a low dose CT (LDCT) scan, possibly confirming the biopsy's findings and thus leading to more early lung cancer detection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Carcinoma | Lung Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liquid Biopsy | Procedure | — | UNRESOLVED |
| Low Dose Computed Tomography of the Chest | Procedure | — | UNRESOLVED |
| Survey Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cohort A (liquid biopsy, optional LDCT)
- description
- Participants undergo collection of blood sample (liquid biopsy), with option to undergo LDCT if liquid biopsy results are positive.
- interventionNames
- Procedure: Liquid Biopsy
- Procedure: Low Dose Computed Tomography of the Chest
- Other: Survey Administration
- type
- EXPERIMENTAL
- label
- Cohort B (LDCT, optional liquid biopsy)
- description
- Participants undergo low dose CT with optional liquid biopsy on the same day as LDCT.
- interventionNames
- Procedure: Liquid Biopsy
- Procedure: Low Dose Computed Tomography of the Chest
- Other: Survey Administration
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Documented written informed consent of the participant. * Age 50-80 years. * Smoking history of \>= 20 pack-years and if quit, quit within 15 years. * Received referral for counseling for lung cancer screening and would qualify for LDCT. * Health Insurance that will pay for a LDCT for lung cancer screening at either City of Hope Duarte, Newport Beach (Newport Diagnostic Imaging), or Lancaster (Renaissance Imaging/Antelope Valley Outpatient Imaging Center). * Willingness to provide blood sample. * English speaking. * Consent to undergo lung cancer screening with either liquid biopsy (LB) or LDCT. Exclusion Criteria: * Symptoms of lung cancer. * Chest CT scan or chest positron emission tomography (PET)/CT within 12 months. * Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer. * Unable to undergo LDCT at either City of Hope Duarte, Newport Beach, or Lancaster.
References
Publications (0)
Data not yet available